glp-1
11 articles tagged with ‘glp-1’
Retatrutide in Canada: Access, Trials, and Approval Timing
Retatrutide is not yet approved in Canada; access is limited to clinical trials. This article outlines the current status, evidence, and realistic timelines for availability.
Tirzepatide vs Retatrutide: Evidence, Mechanisms, Safety
This reference distinguishes randomized trial evidence from extrapolation for tirzepatide and retatrutide, clarifying mechanisms and safety. It highlights the absence of direct head-to-head trials and the limits of current data.
Ozempic in Peptide Research: Context, Tools, and Validation
Ozempic is a GLP-1 receptor agonist used in metabolic research. This article explains how peptide analysis tools, including standard peptides like α-Casein and carbonic anhydrase peptides, support studies of protein structure and function. Learn about FLAG tag applications and how Volta Peptides resources help verify research compounds.
Is Semaglutide a Peptide or a Protein? A Clear Answer for Researchers
Semaglutide is classified as a peptide, not a protein. This article explains the molecular distinction, why it matters for research, and how to verify compound identity using analytical tools and purity standards.
GLP-1 Receptor Agonist Peptides: A 2026 Research Landscape
An overview of the GLP-1 receptor agonist research landscape in 2026, covering semaglutide, tirzepatide, retatrutide, and emerging dual- and triple-agonist peptides.
Semaglutide vs Tirzepatide: A Research Comparison
Comparing the mechanisms, receptor pharmacology, and preclinical profiles of semaglutide and tirzepatide — two of the most studied GLP-1 receptor agonist peptides in modern research.
Novo Nordisk Presents Oral Semaglutide Phase 3a Trial Data at ADA
Novo Nordisk shared recent findings from two phase 3a trials of oral Semaglutide at the American Diabetes Association annual meeting. The drug reduced A1C levels and supported weight loss in type 2 diabetes patients compared to controls. Results from PIONEER 2 and PIONEER 4 trials showed significant improvements in blood sugar control and body weight.
.png)
GLP-1 (7-36) Amide: Incretin Hormone Structure and Role
GLP-1 (7-36) amide serves as a key incretin hormone derived from proglucagon in the gut, stimulating insulin secretion in a glucose-dependent manner. It circulates mainly post-meals at levels peaking at 30-60 pM, but degrades rapidly via DPP-4 with a half-life under 2 minutes. Research highlights its potential for type II diabetes treatment despite stability challenges.
Retatrutide (RETA) Research: Triple Agonist Metabolic Effects
Retatrutide, known online as RETA, acts as a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon pathways in metabolic research. Phase 2 trial data showed up to 17.5% mean body weight reduction at 24 weeks and 24.2% at 48 weeks in the highest-dose group. Studies explore its effects on appetite, glucose control, energy balance, liver fat, and neurological pathways beyond just weight loss.
U.S. Telehealth Platforms for GLP-1 Peptides and Research Suppliers
Licensed U.S. telehealth platforms provide prescriptions for GLP-1 medications such as semaglutide and tirzepatide, along with NAD+ injections and other peptide therapies, shipped directly to patients. These services include online consultations and operate in most states. Research peptide suppliers offer compounds like GLP-1 agonists with high purity levels from independent testing.
Is Tirzepatide a Peptide? Resolving Common Terminology Confusion
Many researchers ask if tirzepatide qualifies as a peptide, along with related queries like tirzepatide versus peptides or if it contains peptides. Tirzepatide is indeed a 39-amino-acid synthetic peptide featuring fatty acid conjugation, which extends its half-life to about 5 days. This guide clarifies the biochemical definition, key differences from native peptides like BPC-157, and why the confusion persists in research contexts.